149 related articles for article (PubMed ID: 32534450)
21. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
22. Expression of N-Myc Downstream-Regulated Gene 2 in Bladder Cancer and Its Potential Utility as a Urinary Diagnostic Biomarker.
Zhang M; Ren B; Li Z; Niu W; Wang Y
Med Sci Monit; 2017 Sep; 23():4644-4649. PubMed ID: 28953854
[TBL] [Abstract][Full Text] [Related]
23. Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma.
Soukup V; Kalousová M; Capoun O; Sobotka R; Breyl Z; Pešl M; Zima T; Hanuš T
Urol Int; 2015; 95(1):56-64. PubMed ID: 25662337
[TBL] [Abstract][Full Text] [Related]
24. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
[TBL] [Abstract][Full Text] [Related]
25. Urinary tissue polypeptide-specific antigen for the diagnosis of bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; García J; Alférez F; González deBuitrago JM; Navajo JA
Urology; 2000 Apr; 55(4):526-32. PubMed ID: 10736496
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer.
Jeong S; Park Y; Cho Y; Kim YR; Kim HS
Clin Chim Acta; 2012 Dec; 414():93-100. PubMed ID: 22944145
[TBL] [Abstract][Full Text] [Related]
27. Detection of bladder cancer with aberrantly fucosylated ITGA3.
Islam MK; Syed P; Dhondt B; Gidwani K; Pettersson K; Lamminmäki U; Leivo J
Anal Biochem; 2021 Sep; 628():114283. PubMed ID: 34102169
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.
Stampfer DS; Carpinito GA; Rodriguez-Villanueva J; Willsey LW; Dinney CP; Grossman HB; Fritsche HA; McDougal WS
J Urol; 1998 Feb; 159(2):394-8. PubMed ID: 9649246
[TBL] [Abstract][Full Text] [Related]
29. Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis.
Eissa S; Matboli M; Essawy NO; Kotb YM
Tumour Biol; 2015 Dec; 36(12):9545-52. PubMed ID: 26138586
[TBL] [Abstract][Full Text] [Related]
30. Urinary cell-free microRNA biomarker could discriminate bladder cancer from benign hematuria.
Piao XM; Jeong P; Kim YH; Byun YJ; Xu Y; Kang HW; Ha YS; Kim WT; Lee JY; Woo SH; Kwon TG; Kim IY; Moon SK; Choi YH; Cha EJ; Yun SJ; Kim WJ
Int J Cancer; 2019 Jan; 144(2):380-388. PubMed ID: 30183088
[TBL] [Abstract][Full Text] [Related]
31. Cell-free lncRNA expression signatures in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
Du L; Duan W; Jiang X; Zhao L; Li J; Wang R; Yan S; Xie Y; Yan K; Wang Q; Wang L; Yang Y; Wang C
J Cell Mol Med; 2018 May; 22(5):2838-2845. PubMed ID: 29516641
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of urine NMP22 point-of-care test for the screening of bladder cancer].
Ihm CH; Kim JM; Sohn YH
Korean J Lab Med; 2007 Apr; 27(2):106-10. PubMed ID: 18094560
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder.
Sánchez-Carbayo M; Herrero E; Megías J; Mira A; Soria F
BJU Int; 1999 Oct; 84(6):706-13. PubMed ID: 10510120
[TBL] [Abstract][Full Text] [Related]
34. Microchips for detection of exfoliated tumor cells in urine for identification of bladder cancer.
Liang L; Wang Y; Lu S; Kong M; Lin Y; Cuzzucoli F; Wang P; Wang S
Anal Chim Acta; 2018 Dec; 1044():93-101. PubMed ID: 30442409
[TBL] [Abstract][Full Text] [Related]
35. Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study.
Ribal MJ; Mengual L; Lozano JJ; Ingelmo-Torres M; Palou J; Rodríguez-Faba O; Witjes JA; Van der Heijden AG; Medina R; Conde JM; Marberger M; Schmidbauer J; Fernández PL; Alcaraz A
Eur J Cancer; 2016 Feb; 54():131-138. PubMed ID: 26761785
[TBL] [Abstract][Full Text] [Related]
36. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
[TBL] [Abstract][Full Text] [Related]
37. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
Lotan Y; OʼSullivan P; Raman JD; Shariat SF; Kavalieris L; Frampton C; Guilford P; Luxmanan C; Suttie J; Crist H; Scherr D; Asroff S; Goldfischer E; Thill J; Darling D
Urol Oncol; 2017 Aug; 35(8):531.e15-531.e22. PubMed ID: 28366272
[TBL] [Abstract][Full Text] [Related]
38. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Agarwal A
J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
[TBL] [Abstract][Full Text] [Related]
39. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
Lee KH
Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
